Mycobacterium tuberculosis-Secreted Tyrosine Phosphatases as Targets Against Tuberculosis: Exploring Natural Sources in Searching for New Drugs

被引:18
|
作者
Mascarello, Alessandra [1 ,2 ,3 ]
Chiaradia-Delatorre, Louise Domeneghini [2 ,3 ]
Mori, Mattia [4 ]
Terenzi, Hernan [2 ,3 ]
Botta, Bruno [1 ]
机构
[1] Univ Roma La Sapienza, Dipartimento Chim & Tecnol Farmaco, Piazzale Aldo Moro 5, I-00185 Rome, Italy
[2] CEBIME UFSC, Ctr Biol Mol Estrutural, Dept Bioquim, Campus Trindade, BR-88040900 Florianopolis, SC, Brazil
[3] Univ Fed Santa Catarina, Campus Trindade, BR-88040900 Florianopolis, SC, Brazil
[4] Ist Italiano Tecnol, Ctr Life Nano Sci Sapienza, Viale Regina Elena 291, I-00161 Rome, Italy
关键词
Tuberculosis; Mycobacterium tuberculosis; tyrosine phosphatases; PtpA; PtpB; RAPID MOLECULAR-DETECTION; RESISTANT TUBERCULOSIS; ADENOSINE-DEAMINASE; DIAGNOSTIC-TOOL; SELECTIVE INHIBITORS; ORIENTED SYNTHESIS; POTENT INHIBITORS; VIRULENCE FACTOR; A-C; MPTPB;
D O I
10.2174/1381612822666160112130539
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Tuberculosis (TB) is an infectious disease caused by Mycobacterium tuberculosis (Mtb), which primarily affects the respiratory tract. Combinations of drugs are used for therapeutic synergism and to prevent the emergence of drug resistant strains, but even first-or second-choice drugs present some disadvantages, such as significant side effects and the need for long duration of treatments. Thus, new strategies for TB control and treatment are highly demanded. In this context, protein tyrosine phosphatases (PtpA and PtpB) are secreted by Mtb within the host macrophage and they have been shown to contribute to Mtb pathogenicity. The understanding of the role of these PTPs has led to interesting anti-TB drugs discovery. Here, we review the current knowledge on these two proteins as targets for novel anti-TB therapies, with particular emphasis on their mechanism of action and current advancements in developing small molecule inhibitors from natural sources.
引用
收藏
页码:1561 / 1569
页数:9
相关论文
共 28 条
  • [21] In vitro interaction profiles of the new antitubercular drugs bedaquiline and delamanid with moxifloxacin against clinical Mycobacterium tuberculosis isolates
    Chandramohan, Yuvaraj
    Padmanaban, Venkatesan
    Bethunaickan, Ramalingam
    Tripathy, Srikanth
    Swaminathan, Soumya
    Ranganathan, Uma Devi
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2019, 19 : 348 - 353
  • [22] Immunogenicity testing of new potential vaccine targets against Mycobacterium tuberculosis by whole blood assay in a population with high TB prevalence
    Walzl, G.
    Black, G. F.
    Stanley, K.
    Loxton, A.
    Chegou, N.
    Golakai, H. J.
    Nene, N.
    Roberts, T.
    Beyers, N.
    Franken, K.
    Friggen, A.
    Ottenhoff, T.
    Klein, M.
    Thiel, B.
    IMMUNOLOGY, 2007, 120 : 57 - 57
  • [23] Not to wake a sleeping giant:: new insights into host-pathogen interactions identify new targets for vaccination against latent Mycobacterium tuberculosis infection
    Lin, May Young
    Ottenhoff, Tom H. M.
    BIOLOGICAL CHEMISTRY, 2008, 389 (05) : 497 - 511
  • [24] Traditional medicine inspired in Silico Drug Discovery to Identify Novel Natural Product Inhibitors against series of Mycobacterium tuberculosis Protein Kinase Targets
    Banerjee, Subhadip
    Saikia, Anil K.
    Adhikari, Anjan
    Debnath, P. K.
    INDIAN JOURNAL OF PHARMACOLOGY, 2014, 46 : S45 - S45
  • [25] Identification of bioactive natural compounds as efficient inhibitors against Mycobacterium tuberculosis protein-targets: A molecular docking and molecular dynamics simulation study
    Miryala, Sravan Kumar
    Basu, Soumya
    Naha, Aniket
    Debroy, Reetika
    Ramaiah, Sudha
    Anbarasu, Anand
    Natarajan, Saravanan
    JOURNAL OF MOLECULAR LIQUIDS, 2021, 341
  • [26] Recognizing drug targets using evolutionary information: implications for repurposing FDA-approved drugs against Mycobacterium tuberculosis H37Rv
    Ramakrishnan, Gayatri
    Chandra, Nagasuma R.
    Srinivasan, Narayanaswamy
    MOLECULAR BIOSYSTEMS, 2015, 11 (12) : 3316 - 3331
  • [27] High-Content Screening Technology Combined with a Human Granuloma Model as a New Approach To Evaluate the Activities of Drugs against Mycobacterium tuberculosis
    Silva-Miranda, Mayra
    Ekaza, Euloge
    Breiman, Adrien
    Asehnoune, Karim
    Barros-Aguirre, David
    Pethe, Kevin
    Ewann, Fanny
    Brodin, Priscille
    Ballell-Pages, Llus
    Altare, Frederic
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2015, 59 (01) : 693 - 697
  • [28] Efflux pump inhibitors as a promising adjunct therapy against drug resistant tuberculosis: a new strategy to revisit mycobacterial targets and repurpose old drugs
    Rodrigues, Liliana
    Cravo, Pedro
    Viveiros, Miguel
    EXPERT REVIEW OF ANTI-INFECTIVE THERAPY, 2020, 18 (08) : 741 - 757